250 related articles for article (PubMed ID: 28011983)
1. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
2. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Carras S; Regny C; Peoc'h M; Gervasoni J; Gressin R; Cahn JY; Molina L
Leuk Lymphoma; 2015; 56(10):2986-8. PubMed ID: 25676034
[No Abstract] [Full Text] [Related]
3. A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Schmit JM; DeLaune J; Norkin M; Grosbach A
Oncol Res Treat; 2017; 40(1-2):46-48. PubMed ID: 28095384
[TBL] [Abstract][Full Text] [Related]
4. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
5. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.
Cheng L; Song Q; Liu M; Wang Y; Yi H; Qian Y; Xu P; Cheng S; Wang C; Wang L; Zhao W
Front Immunol; 2021; 12():702593. PubMed ID: 34322131
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Yanamandra U; Sahu KK; Jain N; Prakash G; Saikia U; Malhotra P
Ann Hematol; 2016 Oct; 95(10):1715-7. PubMed ID: 27324386
[No Abstract] [Full Text] [Related]
8. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.
Sabry W; Wu Y; Kodad SG
Curr Oncol; 2022 Jul; 29(7):5042-5053. PubMed ID: 35877259
[TBL] [Abstract][Full Text] [Related]
10. Plasmablastic lymphoma of the gastrointestinal tract: A rare entity with a dismal prognosis.
Komaranchath AS; Haleshappa RA; Kuntegowdenahalli LC; Kumar RV; Dasappa L; Babu G
Indian J Cancer; 2016; 53(4):529-533. PubMed ID: 28485344
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review.
Lin L; Zhang X; Dong M; Li L; Wang X; Zhang L; Fu X; Sun Z; Wu J; Li Z; Chang Y; Wang Y; Zhou Z; Zhang M; Chen Q
Medicine (Baltimore); 2017 Feb; 96(7):e6171. PubMed ID: 28207555
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
[TBL] [Abstract][Full Text] [Related]
13. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
Nwanwene K; Khan NAJ; Alsharedi M
J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
[TBL] [Abstract][Full Text] [Related]
14. A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report.
Broccoli A; Nanni L; Stefoni V; Agostinelli C; Argnani L; Cavo M; Zinzani PL
BMC Cancer; 2018 Jun; 18(1):645. PubMed ID: 29879938
[TBL] [Abstract][Full Text] [Related]
15. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
16. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
17. Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
Basavaraj A; Kadam M; Kadam DB
J Assoc Physicians India; 2016 May; 64(5):71-72. PubMed ID: 27735156
[TBL] [Abstract][Full Text] [Related]
18. Successful cord blood transplantation for an HIV-negative patient with refractory plasmablastic lymphoma.
Nishi K; Mitani S; Hatanaka K; Imada K
Ann Hematol; 2017 Jun; 96(6):1057-1058. PubMed ID: 28293711
[No Abstract] [Full Text] [Related]
19. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.
Makady NF; Ramzy D; Ghaly R; Abdel-Malek RR; Shohdy KS
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e255-e263. PubMed ID: 33419717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
